Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionCerebral venous sinus thrombosis (CVST) is a rare form of stroke that usually affects young females especially during pregnancy and the postpartum period. Only studies with sample sizes larger than 10 were included.

Thrombosis 40

Thrombosis Outcomes Cancer Risk Factors 40

Stroke Journal

OCTOBER 31, 2024

Stroke, Ahead of Print. Ischemic stroke is one of the leading causes of disability and mortality worldwide. Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention.

Strokes 40

Strokes Stroke Thrombosis Plaque 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page AWP149-AWP149, February 1, 2024. Background:Direct oral anticoagulants (DOACs) are suitable for some patients with cerebral venous thrombosis (CVT). The primary outcome at day 90 (D90) was a composite of CVT recurrence/extension and symptomatic intracranial hemorrhage (sICH). 1-4d, 23.8%

Thrombosis 40

Thrombosis Outcomes Hemorrhage Strokes 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page ATMP62-ATMP62, February 1, 2024. Introduction:Seizures are a common initial manifestation of cerebral venous thrombosis (CVT). The primary outcome was delayed seizure(s), occurring after 7 days from CVT diagnosis.

Thrombosis 40

Thrombosis Risk Factors Hemorrhage Outcomes 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page A19-A19, February 1, 2024. Background:Preceding respiratory tract infections (RTI) due to bacteria or virus has been linked to an increasing risk of stroke likely by potentiating an inflammatory immune response, endothelial dysfunction, platelet activation, and coagulopathy. aureusinfected WT).

Outcomes 40

Outcomes Strokes Stroke Thrombosis 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionCerebral sinus venous thrombosis (CSVT) has traditionally been treated medically with systemic anticoagulation. We included studies that reported outcomes following EVT for CSVT.

Thrombosis 40

Thrombosis Outcomes Strokes Stroke 40

DAIC

MARCH 31, 2025

These results suggest that abelacimab may be safe across the spectrum of bleeding risk and may make it possible to anticoagulate some of the most vulnerable populations who otherwise would not be treated and therefore left unprotected from the risk of stroke. Data from these trials are expected in the second half of 2026.

Atrial Fibrillation 52

Atrial Fibrillation BMI General Cardiology Thrombosis 52

Journal of the American Heart Association

FEBRUARY 14, 2025

We compared procedural complications and clinical outcomes among patients <75 years of age (n=99), those 75 to 84 years of age (n=103), and those 85 years of age (n=71). Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration.

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40

Frontiers in Cardiovascular Medicine

MAY 29, 2024

This study investigates clinical outcomes, aortic remodeling, and abdominal aortic perfusion patterns after TEVAR with the novel Castor device.MethodsFrom November 2020 to June 2023, 29 patients with TBAD involving the LSA were treated with the Castor single-branched stent graft. No in-hospital mortality, paraplegia, or stroke occurred.

Stents 52

Stents Stent Aortic Outcomes 52

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page ATP267-ATP267, February 1, 2024. Introduction:Exposure to high altitude environment is a risk factor of cerebral venous thrombosis (CVT) probably due to the hypercoagulability. Favorable outcome (modified Ranking Score, mRS 0-2) at follow-up was observed in 81.6% respectively.

Thrombosis 40

Thrombosis Risk Factors Hospital Hemorrhage 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP355-AWP355, February 1, 2025. Stroke outcomes were assessed at 24 hours.Results:Exposure to long wavelength red light resulted in a significant reduction in infarct volume following stroke (mice-red 38.817.6 mm3 vs. mice-white 73.315.0 mm3; p<0.01 vs mice-blue 72.927.9

Strokes 40

Strokes Stroke Thrombosis Outcomes 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWMP59-AWMP59, February 1, 2025. Background and Purpose:External counterpulsation (ECP) is a novel noninvasive method used to improve the perfusion of vital organs, which may benefit ischemic stroke patients. Therefore, 184 patients (97.4%) with moderate neurological deficit (mean NIHSS, 8.2)

Strokes 40

Strokes Stroke Hemorrhage Thrombosis 40

Stroke Journal

JANUARY 26, 2025

Stroke, Volume 56, Issue 2 , Page 527-532, February 1, 2025. BACKGROUND:Acute ischemic stroke treatment typically involves tissue-type plasminogen activator (tPA) or tenecteplase, but about 50% of patients do not achieve successful reperfusion. DNase-I, which degrades neutrophil extracellular traps, could improve thrombolytic efficacy.

Hemorrhage 40

Hemorrhage Strokes Stroke Thrombosis 40

Journal of Cardiovascular Pharmacology

MAY 2, 2024

Patient characteristics and clinical outcomes were collected via electronic medical record system. The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stent thrombosis within 12 month.

Outcomes 40

Outcomes Myocardial Infarction Thrombosis Academic 40

Open Heart

JANUARY 6, 2022

Colchicine, a cheap and widely used anti-inflammatory has shown promise in improving cardiovascular outcomes. Results The use of colchicine in patients who underwent PCI significantly reduced MACE outcomes (risk ratio 0.73 (95% CI 0.61 This has been shown to increase the likelihood of further major adverse cardiovascular events (MACE).

Coronary Artery Disease 52

Coronary Artery Disease Thrombosis Stents Stent 52

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATMP117-ATMP117, February 1, 2025. Introduction:Despite timely recanalization, some ischemic stroke patients treated with endovascular thrombectomy experience persistent neurological deterioration. Experimental stroke models have indicated a critical role for platelets in this process.

Strokes 40

Strokes Stroke Thrombosis Outcomes 40

Dr. Smith's ECG Blog

NOVEMBER 15, 2023

Stroke-volume:50 ml. MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies. Left ventricular end-diastolic volume: 99 ml.

Coronary Angiogram 109

Coronary Angiogram Plaque Thrombosis STEMI 109

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page AWP328-AWP328, February 1, 2025. Migraine with aura(MwA) is associated with an increased risk of stroke and adverse vascular outcomes compared to those with migraine without aura (MwoA). Patients with any adverse vascular outcomes before the index ECG were excluded. p < 001).

Atrial Fibrillation 40

Atrial Fibrillation Outcomes Coronary Artery Disease Myocardial Infarction 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. This study aims to investigate the incidence, complications, and outcomes of SAH patients who develop HIT.MethodsICD‐9‐CM and ICD‐10‐CM codes were used to query the National Inpatient Sample for patients with SAH between 2010 and 2019.

Hemorrhage 40

Hemorrhage Aneurysm Outcomes Thrombosis 40

Stroke Journal

NOVEMBER 27, 2024

Stroke, Volume 56, Issue 1 , Page 5-13, January 1, 2025. BACKGROUND:Lack of a dedicated thrombectomy device for cerebral venous thrombosis hinders the recanalization ability of endovascular treatment (EVT). The primary efficacy outcome was the proportion of immediate complete recanalization during EVT.

Thrombosis 40

Thrombosis Stent Stents Hemorrhage 40

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page A134-A134, February 1, 2024. In severe OHSS, increases in capillary permeability can result in hemoconcentration and hypercoagulability leading to thrombotic events, including stroke and cerebral venous thrombosis. were included from each dataset.

Thrombosis 40

Thrombosis Inpatient Embolism Myocardial Infarction 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionPediatric patients presenting with atypical stroke symptoms pose a diagnostic challenge, which often causes delays in management. Around a quarter of pediatric stroke patients will present with new onset seizures.

Pediatrics 40

Pediatrics Strokes Stroke Quality of Life 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATMP85-ATMP85, February 1, 2025. However, long-term outcomes remain poorly described, and the prognostic significance of the radiographic findings is uncertain.Methods:We extracted demographics and clinical variables for all infants with DMVT at our institution from 2007 to 2023.

Thrombosis 40

Thrombosis Hemorrhage Congenital Outcomes 40

Journal of Cardiovascular Electrophysiology

DECEMBER 4, 2024

However, the presence of residual trabeculation did not contribute to PDL or device-related thrombosis at follow-up or affect the clinical outcomes. The clinical outcomes were compared between patients with and without angiographically detected residual trabeculation. vs. 1.4%, p =0.50; 6.9% vs. 6.0%, p =0.69, respectively).

Thrombosis 40

Thrombosis Atrial Fibrillation Outcomes Research 40

Open Heart

DECEMBER 29, 2022

Methods A search was conducted on five databases for randomised controlled trials (RCTs) conducted between 1 January 2000 and 17 July 2022, which included an ADP-specific platelet function assays and P2Y 12 antagonists as part of dual antiplatelet therapy (DAPT) and have reported the efficacy and/or safety outcomes.

Myocardial Infarction 52

Myocardial Infarction Thrombosis Stent Stents 52

Stroke: Vascular and Interventional Neurology

AUGUST 26, 2024

Stroke: Vascular and Interventional Neurology, Ahead of Print. The most common cerebrovascular disease complicating bacterial meningitis are cerebral infarctions (9%25%), intracerebral hemorrhage (1%7%), cerebral venous thrombosis (1%10%), and subarachnoid hemorrhage (1%5%).Streptococcus

Cerebrovascular Disease 40

Cerebrovascular Disease Thrombosis Hemorrhage Outcomes 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. In order to improve treatment outcomes in these difficult cases, the use of stent‐assisted embolization has been attempted in endovascular treatment of intracranial aneurysms.

Aneurysm 40

Aneurysm Stent Stents Hemorrhage 40

Open Heart

NOVEMBER 28, 2023

Eligible were all aetiological studies evaluating risk of cardiovascular outcomes after exposure to common RTIs within any follow-up duration. to 11.0)), stroke (3.5 (1.2 to 44.9)) and deep venous thrombosis (7.8 (4.3 to 4.9)) and stroke (2.6 (95% Evidence was pooled using random-effects models if data allowed.

Myocardial Infarction 52

Myocardial Infarction COVID-19 Cardiovascular Disease Thrombosis 52

DAIC

FEBRUARY 18, 2025

Previous studies about heart valve disease have focused on procedural or device outcomes, and less on patient-centered and disease-related outcomes that are relevant to patients physical and mental well-being and quality of life. tim.hodson Tue, 02/18/2025 - 16:41 Feb. tim.hodson Tue, 02/18/2025 - 16:41 Feb.

Heart Valves 52

Heart Valves Quality of Life Cardiothoracic Outcomes 52

Stroke: Vascular and Interventional Neurology

OCTOBER 2, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue 6 , November 1, 2023. BackgroundProcedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. Similarly, the rate of in‐stent thrombosis was not significantly different between the 2 groups (1.8%

Hemorrhage 40

Hemorrhage Thrombosis Stents Stent 40

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP7-ATP7, February 1, 2025. Introduction:Venous thromboembolism (VTE)manifesting as deep vein thrombosis (DVT) and pulmonary embolus (PE) and arterial thromboembolism (ATE) manifesting as acute ischemic stroke (AIS) result in ~1 million US deaths annually.

Thrombosis 40

Thrombosis Pulmonary Strokes Stroke 40

Circulation

OCTOBER 24, 2023

The primary endpoint was the net clinical benefit as a composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding at 1 year after the index procedure in the intention-to-treat population. versus 3.4%; HR, 0.35 [95% CI, 0.20–0.61];P<0.001).Conclusions:This

Stents 40

Stents Stent Myocardial Infarction Thrombosis 40

DAIC

JANUARY 23, 2024

3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heart attack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP39-ATP39, February 1, 2025. Outcomes were assessed at 30- and 90-days. The primary outcome for which the trial was powered was adherence (completing 80% of sessions). Secondary outcomes included percentage of sessions completed and pain/discomfort scores from patient diaries.

Blood Pressure 40

Blood Pressure Thrombosis Outcomes Strokes 40

Circulation

NOVEMBER 11, 2024

A meta-analysis was performed on primary outcomes of major adverse cardiac events (MACE) and all-cause mortality. A random-effects model was used for outcomes with high heterogeneity.Results:We included 4 RCTs with 3173 patients comparing FFR-guided CR with culprit-only PCI in patients with STEMI and multivessel coronary artery diseases.

Coronary Artery Disease 40

Coronary Artery Disease Myocardial Infarction STEMI Thrombosis 40

Cardiology Update

FEBRUARY 14, 2024

In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stent thrombosis, and repeat revascularization.

Myocardial Infarction 52

Myocardial Infarction Coronary Artery Disease Thrombosis Research 52

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2024

vs. 30.4%, p =0.07) and device related thrombosis (4.5% Results Patients were younger in the combined ( n =72) than in the control group ( n =144, 70.27.3 years, p <0.001) but otherwise comparable with a mean CHA 2 D 2 -VASc score of 4.21.1 and 4.41.2 ( p =0.26) and HAS-BLED score of 2.20.8 and 2.30.7 ( p =0.34). Both major (1.4%

Ablation 40

Ablation Arrhythmia Thrombosis Echocardiogram 40